Key statistics dashboard for Aytu BioPharma, Inc. (AYTU). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets.
Stock Data
| Price | $1.97 |
| Market Cap | $21M |
| Beta | 0.28 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.46 |
| Price / Book | 0.60 |
| P/S | 0.38 |
| P/FCF | 12.99 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 62.50% |
| EBIT Margin | -55.53% |
| EBITDA Margin | -48.28% |
| Operating Margin | -26.79% |
| Net Margin | -60.17% |
Financial Health
| Current Ratio | 1.12 |
| Quick Ratio | 1.00 |
| Cash Ratio | 0.45 |
| Debt / Equity | 0.65 |
| Debt / Assets | 20.54% |
| Interest Coverage | -6.76 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -3.20 |
Per-Share Data
| Revenue per share | 5.38 |
| Book Value per share | 3.34 |
| Cash per share | 2.54 |
| FCF per share | 0.16 |
| Tangible Book Value per share | -0.70 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 5 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 5 |
| Avg rating (1-5) | 1.00 |
Related companies: ADAP · ALUR · ANL · BFRI · EKSO · GOVX · NVNO
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of AYTU: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks